Recent journal editorials have highlighted the challenges surrounding the complex, emotive and high-profile issue of funding cancer drugs.1^,2 In particular, the UK coalition Government's proposal for a cancer drug fund, and the consequent undermining of the National Institute for Health and Clinical Excellence (NICE) in its evaluation of such drugs, have been called into question. There has also been the recent heated reaction to NICE's …